title: Synergistic effects of antimicrobial peptides and antibiotics against Clostridium difficile.
abstract: Accelerating rates of health care-associated infections caused by Clostridium difficile, with increasing recurrence and rising antibiotic resistance rates, have become a serious problem in recent years. This study was conducted to explore whether a combination of antibiotics with human antimicrobial peptides may lead to an increase in antibacterial activity. The in vitro activities of the antimicrobial peptides HBD1 to HBD3, HNP1, HD5, and LL-37 and the antibiotics tigecycline, moxifloxacin, piperacillin-tazobactam, and meropenem alone or in combination against 10 toxinogenic and 10 nontoxinogenic C. difficile strains were investigated. Bacterial viability was determined by flow cytometry and toxin production by enzyme-linked immunosorbent assay (ELISA). When combined at subinhibitory concentrations, antimicrobial peptides and antibiotics generally led to an additive killing effect against toxinogenic and nontoxinogenic C. difficile strains. However, LL-37 and HBD3 acted in synergism with all the antibiotics that were tested. Electron microscopy revealed membrane perturbation in bacterial cell walls by HBD3. In 3 out of 10 toxinogenic strains, HBD3, LL-37, piperacillin-tazobactam, and meropenem administration led to an increased toxin release which was not neutralized by the addition of HNP1. Antimicrobial peptides increase the bacterial killing of antibiotics against C. difficile regardless of the antibiotics' mode of action. Membrane perturbation in or pore formation on the bacterial cell wall may enhance the uptake of antibiotics and increase their antibacterial effect. Therefore, a combination of antibiotics with antimicrobial peptides may represent a promising novel approach to the treatment of C. difficile infections.
authors.affiliation: Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart, Germany University of Tübingen, Tübingen, Germany.
authors.forename: Sabine
authors.initials: S
authors.lastname: Nuding
authors.affiliation: Institute of Laboratory Medicine, Alb Fils Kliniken, Göppingen, Germany.
authors.forename: Tina
authors.initials: T
authors.lastname: Frasch
authors.affiliation: Department of Dermatology, Eberhard Karls University, Tübingen, Germany.
authors.forename: Martin
authors.initials: M
authors.lastname: Schaller
authors.affiliation: Department of Internal Medicine I, Robert-Bosch-Hospital, Stuttgart, Germany.
authors.forename: Eduard F
authors.initials: EF
authors.lastname: Stange
authors.affiliation: Institute of Laboratory Medicine, Alb Fils Kliniken, Göppingen, Germany lutz.zabel@af-k.de.
authors.forename: Lutz T
authors.initials: LT
authors.lastname: Zabel
mesh_terms: D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D016360:Clostridioides difficile / Q000187:drug effects*; D004357:Drug Synergism; D005434:Flow Cytometry; D008826:Microbial Sensitivity Tests; D010455:Peptides / Q000494:pharmacology*
chemical_list: D000900:Anti-Bacterial Agents; D010455:Peptides